The MarketWatch News Department was not involved in the creation of this content. -- Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals ...

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...

The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic progression-free survival for metastatic hormone-sensitive prostate cancer. 2.

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

$10.4 billion invested in internal research and development projects, and Approximately $8.8 billion invested in business development transactions, primarily reflecting the Metsera acquisition and the ...

In an Untitled Letter, regulators said Facebook promotions for Pfizer’s lymphoma therapy overstated its approved use and ...

While this year’s Super Bowl will be filled with more pharma ads than ever before, one big name will be missing from the roster. Pfizer, which has run ads during the Big Game for the past two years, ...

Pfizer (PFE) is set to report Q4 earnings on Tuesday, February 3, before the market opens, with expectations pointing to another challenging quarter. Wall Street forecasts EPS of $0.57, down 9.5% year ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile dysfunction — two ...

In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Pfizer, with a price target of $28.00. According to TipRanks, Bansal is a 5-star analyst with an average return of 9 ...

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated ...